Lung Cancer Europe

Startseite
Schweiz
Bern
Lung Cancer Europe

Kontaktinformationen, Karte und Wegbeschreibungen, Kontaktformulare, Öffnungszeiten, Dienstleistungen, Bewertungen, Fotos, Videos und Ankündigungen von Lung Cancer Europe, Nichtregierungsorganisation (NRO), Effingerstrasse 40, Bern.

🌍 European network of lung cancer organisations
🫁 Turning evidence into advocacy
🔬 Earlier diagnosis & testing
💊 Equal access to lung cancer treatment & care
🤝 Better support for people affected by lung cancer
🇪🇺 Working for change across Europe

31/08/2026

Too many people with lung cancer still face delays between first seeking help, seeing a specialist, getting a diagnosis and starting treatment.

Our new position statement calls for integrated rapid referral pathways across Europe, linking primary, secondary and specialist care so people move through the system faster and with fewer gaps.

In our 7th Report, 27.3% of respondents waited more than a month to see a lung specialist, 28.2% waited more than a month for a diagnosis after specialist review, and 43.2% did not start treatment within one month of diagnosis.

Lung cancer needs faster, joined-up referral pathways.

Read the full position statement via the link in comments.

30/08/2026

Our 2026 Get Checked campaign is focusing on the space where lung cancer symptoms first meet the healthcare system.

We’re speaking to people who have experienced lung cancer symptoms and the path to diagnosis, and we’re listening to healthcare professionals about what those first conversations look like from their side.

As part of that work, we spent time last week with the lung cancer team at Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, at Royal Albert Edward Infirmary.

The visit gave us the chance to follow what happens once someone enters the diagnostic pathway, from referral and MDT co-ordination through the rapid diagnostic pathway, specialist nursing, pathway navigation, biopsy, supportive services and the lung cancer MDT.

Even working in lung cancer, seeing just how much happens behind the scenes for every single person was quite something. The level of detail, the time spent discussing individual cases, the communication between different parts of the team and the care taken to make sure people are supported as seamlessly as possible really was incredible.

It was very clearly a team effort. Everyone we met was generous with their time, passionate about what they do and incredibly serious about providing a joined-up, patient-centred service.

A huge thank you to Vee, who organised the day so meticulously, and to Dr Simon Dawson, Caroline, Lee, Libby, Katie, Cath, Sue and Karen for sharing their time, knowledge and experience with us.

Vee is also part of Lung Cancer Nursing UK (LCNUK), one of Lung Cancer Europe’s member organisations, so it was particularly good to spend time with a team so closely connected to the wider lung cancer nursing community.

For Get Checked 2026, we want to understand the whole picture: what it feels like to notice symptoms and seek help, what those first conversations look like in primary care, and what happens next when someone is referred.

Thank you to the whole Wigan team for opening the door and letting us see the work that normally happens behind it. 💙

29/08/2026

Blood tests are becoming an increasingly useful way to learn more about lung tumours.

In NSCLC, ctDNA can help identify genetic changes that may guide treatment. Newer research suggests ctRNA can add more information, especially for some gene fusions.

At WCLC 2026, new data from 602 people with NSCLC found that adding ctRNA increased detection of actionable gene rearrangements by 38.7% compared with ctDNA alone.

Liquid biopsy does not replace tissue testing in every situation, but using DNA and RNA together may help find changes that one test alone could miss.

Read more via the link in comments.

28/08/2026

Most of us never think about our thymus, but a new study suggests it might be important in lung cancer radiotherapy.

The thymus is a small gland in the upper chest that helps the body develop and train T cells, which are an important part of the immune system.

A new Annals of Oncology study found that, in people having radiotherapy for NSCLC, unintended radiation to the thymus was linked with worse outcomes.

This raises questions as lung cancer treatment becomes more precise, but doesn’t mean radiotherapy is harmful overall or that practice should change straight away.

As Hugo Aerts, one of the study’s senior authors, told us:

“The next question we hope to answer is whether protecting the thymus during radiation therapy can help preserve immune health and improve outcomes.”

Could the thymus become another organ doctors try to protect during lung cancer radiotherapy?

27/08/2026

The fourth speaker is confirmed for our small cell lung cancer webinar.

Joining our three clinicians on 3 September is Irina, who lives in Finland and has been living with small cell lung cancer since 2025.

She’ll share her own experience of diagnosis, treatment and access to care. That lived experience is an essential part of understanding where progress is being made, and where gaps still exist.

Small cell lung cancer has been overlooked for a long time. This session will look honestly at recent advances, while also asking what those advances mean for people living with SCLC across Europe.

Free. Online. 3 September, 15:00 CEST.

Register now 👉 https://lungcancereurope.eu/sclc-webinar-2026

26/08/2026

A lung cancer screening scan is only the first step.

If a scan finds something suspicious, people need clear follow-up, enough diagnostic capacity, agreed pathways and timely access to specialist care.

That is one of the practical issues highlighted in a new report from Lung Cancer Policy Network, which looks at what European countries are learning as lung cancer screening moves into wider implementation.

The report also focuses on reaching people at highest risk, reducing barriers to taking part and integrating smoking cessation support.

These priorities closely align with Lung Cancer Europe’s own call for timely and equitable access to screening, early diagnosis and specialist care across Europe.

Lung Cancer Europe is a member of Lung Cancer Policy Network.

Read more via the link in comments.

25/08/2026

One week to go. The survey for our 12th Lung Cancer Europe Report opens on 1 September.

This year, we are looking at quality of life and support needs, and we want to hear from people living with lung cancer and those who care for them about life beyond treatment itself.

For more than a decade, our Annual Reports have brought together evidence and lived experience from across Europe and used it to support our advocacy, policy work and conversations with decision makers.

The 12th Report will continue that work.

Survey opens 1 September 2026.

24/08/2026

What do jellyfish and fireflies have to do with lung cancer research?

They helped researchers build a new way to track tumours.

Scientists in Scotland have developed an imaging system that combines fluorescent proteins, firefly light-producing enzymes and PET imaging to follow tumours from the whole body down to individual cells.

The system has been tested in models of lung adenocarcinoma and liver cancer. It could help researchers study how tumours grow, spread and respond to treatment in much greater detail.

This is a research tool, not a scan or treatment being used in people with lung cancer. It gives scientists a new way to connect what they see on whole-body imaging with what is happening inside a tumour.

And yes, the jellyfish and fireflies really are part of the story.

Read more via the link in comments.

23/08/2026

‼️ A big finding in younger-onset lung cancer.

A new international analysis of 14,246 people with non-small cell lung cancer found that younger adults were significantly more likely to have genetic changes that can be matched with targeted treatments.

Nearly 58% of younger adults had guideline-recommended actionable alterations, compared with around 45% of people aged 55 and over.

EGFR, ALK and ROS1 alterations were more common in the younger group. Researchers also found differences in other genomic and immune features, suggesting that the biology of NSCLC may alter with age.

The research, led by Chinmay Jani and Gilberto Lopes with colleagues from Sylvester Comprehensive Cancer Center, Labcorp and Dana-Farber Cancer Institute, will be presented at the IASLC World Conference on Lung Cancer in Seoul on 14 September.

Biomarker testing is essential across NSCLC, whatever someone’s age. But finding such a high proportion of actionable alterations in younger adults is especially important because lung cancer can be less expected in this group and diagnosis may come later.

More on what the researchers found and how it fits with what we already know about early-onset lung cancer 🔗 in comments below.

22/08/2026

Three positive Phase 3 lung cancer trial results have been reported this week, across three different biomarker-defined groups.

HER2-mutant NSCLC
In DESTINY-Lung04, trastuzumab deruxtecan improved progression-free survival compared with first-line chemotherapy plus immunotherapy in people with advanced HER2-mutant NSCLC who had not previously received treatment.

EGFR-mutant NSCLC with MET-driven resistance
In SAFFRON, osimertinib plus savolitinib improved both progression-free survival and overall survival compared with chemotherapy in people whose cancer had progressed on osimertinib and had MET amplification.

EGFR-mutant NSCLC after EGFR-targeted treatment
In PANKU-Lung01, the EGFR × HER3 bispecific antibody-drug conjugate izalontamab brengitecan improved progression-free survival compared with platinum chemotherapy after progression on EGFR-targeted treatment.

These are topline Phase 3 results, so the full data are still to come, including detailed efficacy and safety results.

Adresse

Effingerstrasse 40
Bern
3008

Webseite

https://linktr.ee/lungcancereur

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Lung Cancer Europe erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.